Aprobarbital

Summary

Aprobarbital (CHEMBL7863) is an approved small molecule (ATC N05CA05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA05
• Chemistry: 210.23 Da · C10H14N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL7863
Name	Aprobarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6464
ChEBI	CHEBI:2791
ATC	N05CA05
Molecular formula	C10H14N2O3
Molecular weight	210.23
InChIKey	UORJNBVJVRLXMQ-UHFFFAOYSA-N

SMILES: CC(C)C1(C(=O)NC(=O)NC1=O)CC=C

IUPAC name: 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione

ChEBI definition: A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by an isopropyl and a prop-1-en-3-yl group at position 5.

Also known as: Alurate, Aprobarbital, NSC-120769, APROBARBITAL

Patent coverage: 1,241 distinct patent families (4,837 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 4,810 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).